p<0.001). Interestingly, we detected a significant decrease of iNOS mRNA levels in hypoxic brains. LEV treatment did not alter HIF-1α accumulation either in normoxic or hypoxic brains (P0, P7). Moreover, significant changes of VEGF and NOS mRNA levels did not occur with the exception that hypoxia-induced decreased iNOS levels
were not observed in P0 brains. We conclude that acute systemic hypoxia differentially affects expression of HIF-1-regulated vasoactive factors in the newborn mouse brain. Of clinical importance, LEV treatment did not alter crucial HIF-1-regulated neuroprotective mechanisms.
Introduction
Acquired brain lesions as a consequence of perinatal hypoxia are significant causes of neonatal morbidity as well as of severe long-term disability including senso-motor disabilities, postneonatal epilepsy, cognitive and behavioral disturbances (Woodward et al., 2006) . Neonatal hypoxic brain injury develops as sequelae of pulmonary immaturity, systemic hypoperfusion, disturbed cerebrovascular autoregulation as well as neonatal complications, e.g. asphyxia, sepsis, apnoic spells and seizures whereas currently no specific neuroprotective treatment is available. The complex hypoxia-induced neurotoxic cascade including excitotoxic, inflammatory and metabolic pathways sustains secondary neurodegeneration during reoxygenation period (Jensen et al., 2006) . Of note, regional and cellular vulnerability to hypoxia is age-specific and determined by distinct developmental factors including paracrine metabolic and vascoactive pathways as well as growth factors (Jensen, 2006) . In this context, hypoxia-inducible transcription factor-1 (HIF- 
Results
HIF-1α protein, HIF-1-regulated genes as well as hypoxia-inducible but HIF-1-independent vasoactive factors were determined in developing mouse brains at P0
and P7 upon exposure to severe systemic hypoxia with and without LEV treatment.
Changing HIF-1α protein accumulation in the developing mouse brain during normoxia.
Low levels of HIF-1α protein were detectable at normoxic conditions in whole brain lysates at both developmental ages P0 and P7 as assessed by Western blot analysis ( Fig. 1 ) whereby signals were somewhat more prominent at P0 than at P7.
Immunohistochemical staining of HIF-1α revealed protein expression in the developing cerebral cortex and hippocampus: HIF-1α protein was weakly expressed in normoxic mouse brains at P0 and P7 ( Fig. 2 ; non-treated group). Positive stainings were predominantly found in neuron-like cells in the upper cortical layers (layers II/III) at both ages. Of note, HIF-1α-positive cells were more prominent in cerebral cortex at P0 ( Fig. 2A , B) than P7 (Fig. 2I, J) .
Elevated HIF-1α protein levels in the developing mouse brain exposed to hypoxia.
Systemic hypoxia (8% O 2 , 6 h) led to significant accumulation of HIF-1α protein in the developing mouse brain at both developmental ages (P0 and P7) compared to controls. Fig. 1 shows representative Western blot data of HIF-1α protein accumulation in hypoxic mouse brain compared to normoxic tissues demonstrating significant increase of HIF-1α in response to systemic hypoxia at P0 as well as at P7.
As the developing cerebral cortex is highly vulnerable to hypoxia, we assessed spatial and cellular cortical HIF-1α expression by immunohistochemical analysis. We 
Differential expression of HIF-1-regulated target genes in the hypoxic brain.
To determine the functional activation of cerebral HIF-1α protein due to acute systemic hypoxia, we analyzed mRNA levels of vasoactive HIF-1 target genes in homogenates of developing mouse brains exposed to systemic hypoxia (8% O 2 ) for 6h. When exposed to reduced oxygenation, cerebral VEGF mRNA levels increased 1.7-fold in the untreated P0 (p<0.05) and more strongly (9.1-fold), in the P7 animals ( Fig. 4A ; hypoxia group; p<0.001) compared to normoxic controls. Unexpectedly, cerebral mRNA levels for iNOS were significantly decreased in the hypoxic brains (P0, P7) when compared to normoxic controls (Fig. 4B, p<0 .001).
Expression of HIF-1-independent hypoxia-inducible genes.
Gene expression of HIF-1-independent genes (eNOS, nNOS, caspase-3) known to be involved in the complex cascade of hypoxic fetal brain injury was not significantly different between normoxic and hypoxic brains of developmental age P0 and P7
during the acute stage of hypoxic stress ( Table 1) .
Effects of LEV treatment during normoxia.
To evaluate possible adverse effects, we compared cerebral HIF-1α protein and target gene expression upon saline-and LEV-treatment under normoxic conditions.
LEV treatment did not significantly change HIF-1α protein accumulation in normoxic brains at both P0 and P7 developmental ages compared to non-treated tissues as assessed by Western blot (Fig. 1) . Furthermore, immunohistochemical analysis did not show differences in the number and intensity of cortical HIF-1α-positive cells when comparing non-treated ( Fig. 2 A, I ), saline-( (table 1) were observed 6 h after administration of LEV at a dose of 50 mg/kg to normoxic animals compared to controls.
Effects of LEV treatment upon short-term systemic hypoxia.
To study possible effects of LEV on hypoxia-induced alterations of cerebral HIF-1α protein and specific target gene expression, saline-treated and LEV-treated hypoxic mouse brains were compared. LEV did not modify HIF-1α protein accumulation in hypoxic brains at either P0 or P7 compared to non-treated hypoxic controls ( Fig. 1) .
At the cellular level, intensity of HIF-1α-positive cells was not different between hypoxic LEV-treated brains ( Fig. 2 H, P) and hypoxic non-treated ( Fig. 2 E, M) and saline-treated tissues of the corresponding age group (Fig. 2 G, O) as assessed in hypoxic cerebral cortex (Fig. 2 ) and in hippocampus (data not shown) by immunohistochemical analysis. The hypoxia-induced increase of cerebral VEGF mRNA levels in animals exposed to hypoxia was similar in vehicle-and LEV-treated hypoxic animals of both P0 and P7 age group (Fig. 4A) . Interestingly, hypoxia-induced decrease of iNOS mRNA levels was not present in the LEV-treated group at P0 (Fig. 4B ) whereas there was a significant difference at P7 between hypoxic and normoxic brains of LEV-treated mice (Fig. 4B ) similar to that observed in non-treated animals.
Messenger RNA expression of HIF-1-independent genes (eNOS, nNOS, caspase-3)
was found at similar levels in vehicle-and LEV-treated hypoxic brains at age P0 and P7 (Table 1) indicating no changes in response to LEV administered at a dose of 50 mg/kg.
To examine whether LEV enhances sensitivity to apoptotic cell death in normoxic and hypoxic brains were performed, Western blot analysis for anti-apoptotic (Bcl-2 and
Bcl-X L ) and pro-apoptotic (Bax) proteins (Fig. 5A ). Although cerebral Bcl-2 signals
were significantly lower at P0 than at P7 during normoxia and hypoxia (Fig. 5B) , there was no significant difference in Bcl-2 accumulation between normoxic and hypoxic brains (Fig. 5A ). LEV treatment did not induce significant changes of Bcl-2, Bcl-X L and Bax levels during normoxia and hypoxia at either P0 or P7 (Fig. 5A ).
Discussion
Upon reduced oxygen supply to very young mice (P0 and P7) we observed, firstly, that HIF-1 is rapidly induced in developing cortical neurons. Secondly, we noted that specific vasoactive target genes are differentially affected by this acute hypoxic distress. Thirdly, LEV-treatment did not alter accumulation of HIF-1α protein nor the vasoactive HIF-1 target gene VEGF indicating that LEV does not affect crucial endogenous modulators of cerebral adaptation to hypoxia at early stage of brain maturation. Interestingly, LEV prevented hypoxia-induced decrease of iNOS mRNA levels at P0 but not at P7 suggesting specific age-dependent differential effects.
Finally, our data shows that LEV does not markedly change expression of HIF-1-independent NOS in the normoxic or hypoxic newborn brain. In summary, this study shows that HIF-1 represents a rapidly responsive and adaptable system of the newborn brain to severe short-term hypoxia at very early developmental stage, and that acute hypoxia differentially affects expression of HIF-
HIF-1 is a readily available

1-regulated vasoactive factors in newborn mouse brain. Accumulation of HIF-1α
protein as well as expression of HIF-1-dependent and independent genes were not altered by LEV treatment indicating no influence of LEV on crucial endogenous neuroprotective mechanisms of the developing newborn brain.
Experimental Procedure
Animal experiments. C57BL/6 wild-type mice were exposed to systemic hypoxia (8% O 2 ) without concomitant experimental ischemia at postnatal day 0 (P0, n=40) and day 7 (P7; n=38) providing a model for the preterm human neonate at midgestation (P0) and the near-term neonate (P7) (Dobbing et al., 1979) . Duration of hypoxic incubation was 6h (Hypoxic Workstation INVIVO Porphobilinogen deaminase (PBGD) and ß-actin were used as housekeeping genes.
The following primers and TaqMan probes based on published reports were used: and P7 (lanes 1-4) exposed to normoxia or acute systemic hypoxia. There were no significant differences in either Bcl-2 and Bcl-Xl or Bax protein contents between saline-and LEV-treated brains. B. Age-dependent difference in Bcl-2 levels (mean±SEM) normalized to β-actin assessed by densitometric analysis.
